Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-negative,ER-positive) and gBRCA or HDR-positive Metastatic Breast Cancer(LUZERN) (LUZERN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04240106
Recruitment Status : Not yet recruiting
First Posted : January 27, 2020
Last Update Posted : January 28, 2020
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
MedSIR

Brief Summary:

This study evalues the efficacy -as determined by the clinical benefit rate (CBR)- of niraparib in combination with AIs in unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer patients harboring either gBRCAms or gBRCAwt and HRD.

The planned number of patients is 23.

Investigational product is Niraparib 100 mg and the study dose will be 200mg or 300mg daily continuously in 28-day cycles plus aromatase Inhibitors.

Total study duration is 36 months and until 5 years of follow up.


Condition or disease Intervention/treatment Phase
Breast Cancer Breast Cancer Metastatic Drug: Niraparib 100 MG Drug: Aromatase Inhibitors Phase 2

Detailed Description:

This is a Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib plus Aromatase Inhibitors for Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Metastatic Breast Cancers with either Germline BRCA-mutated or Germinal BRCA-wild-type and Homologous Recombination Deficiency (HRD).

The main objetive is to assess the efficacy -as determined by the clinical benefit rate (CBR)- of niraparib in combination with AIs in unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer patients harboring either gBRCAms or gBRCAwt and HRD.

Upon meeting all selection criteria, patients enrolled in the study will receive the combination of niraparib either 300 mg or 200 mg orally (according to baseline criteria described in Table 4), once daily, flat- fixed, continuously in 28-day cycles and AI that must be identical to the last AI-containing regimen.

A total of 23 patients will be recruited as follows:

  • Stage I: N=6 patients in the cohort A;
  • Stage II: N=8 patients in the cohort A; N=9 patients in the exploratory cohort B

The total duration of the study period is 36 months follow until 5 years of follow up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 23 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Multicenter, open-label, single-arm, two-cohort, Simon's two- stage phase II clinical trial.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib Plus Aromatase Inhibitors for (HR)-Positive/ (HER2)-Negative Metastatic Breast Cancers With Either Germline BRCA-mutated or Germinal BRCA-wild-type and Homologous Recombination Deficiency (HRD)
Estimated Study Start Date : March 2020
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Niraparib 100mg in combination with Aromatase Inhibitors
Upon meeting all selection criteria, patients enrolled in the study will receive the combination of niraparib either 300 mg or 200 mg orally, once daily, flat- fixed, continuously in 28-day cycles plus aromatase Inhibitors.
Drug: Niraparib 100 MG
Niraparib 200 or 300 mg daily (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
Other Name: ZEJULA

Drug: Aromatase Inhibitors
Aromatase Inhibitors beginning on Day 1 and continuing through Day 28 of every 28-day cycle.




Primary Outcome Measures :
  1. Clinical benefit rate (CBR) of niraparib in combination with AIs in unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer patients harboring either gBRCAms or gBRCAwt and HRD [ Time Frame: Baseline up to 24 weeks ]
    The CBR as best response, defined as the percentage of patients who experience a complete response, partial response or stable disease for at least 24 weeks and assessed by modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria


Secondary Outcome Measures :
  1. Efficacy determinated by the Progression-free Survival (PFS) [ Time Frame: Baseline up to 36 months ]
    PFS is defined as the time from the date of the first dose of study treatment until the first documented PD based on RECIST v1.1. or death due to any cause, whichever occurs first based on local investigator's assessment according to RECIST criteria v1.1.

  2. Efficacy determinated by the Objective Response Rate (ORR) [ Time Frame: Baseline up to 36 months ]
    The ORR is defined as the number of patients with CR and PR divided by the number of patients in the analysis set. Tumor response will be defined as best response based on local investigator's assessment according to RECIST criteria v.1.1.

  3. Efficacy determined by Duration of Response (DoR) [ Time Frame: Baseline up to 36 months ]
    DoR is defined as the time from first documented CR or PR until disease progression or death from any cause, based on local investigator's assessment according to RECIST criteria v1.1.

  4. Efficacy determined by Overall survival (OS) [ Time Frame: Baseline up to 36 months ]
    OS is defined as the time from the date of first dose of study treatment until death by any cause or the last date the patient was known to be alive.

  5. Efficacy determined by Time to response (TTR) [ Time Frame: Baseline up to 36 months ]
    Time to response (TTR) is defined as the time from the date of first dose of study treatment to the first objective tumor response observed for patients who achieved a Complete response (CR) or parcial response (PR).

  6. Incidence of treatment-related AEs Grade 3 and 4 and serious adverse events (SAEs) [Safety] [ Time Frame: Baseline up to 36 months ]
    Safety will be measured by using the National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) v.5.0.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Patients have been informed about the nature of study, including the exploratory sub-study and has agreed to participate and signed the informed consent prior to participation in any study- related activities.
  • 2. Male or female patients ≥ 18 years of age.
  • 3. Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1 which the Investigator believes is stable at the time of screening.
  • 4. Life expectancy ≥16 weeks.
  • 5. Patients have a histologically and/or cytologically confirmed diagnosis of breast cancer.
  • 6. Patients have radiologic evidence of inoperable locally recurrent or metastatic breast cancer (MBC) that are not candidates for curative intent.
  • 7. Patients have human epidermal growth factor receptor 2 (HER2)- negative breast cancer (based on most recently analyzed biopsy) defined as a negative in situ hybridization (ISH) test or an immunohistochemistry (IHC) status of 0, 1+, or 2+ (if IHC 2+, a negative ISH test is required) by local laboratory testing.
  • 8. Patients have hormone receptor (HR)-positive breast cancer (based on most recently analyzed biopsy) defined as estrogen receptor (ER) and/or progesterone receptor (PgR) with ≥10% of tumor cells positive for ER and/or PgR by IHC irrespective of staining intensity.
  • 9. [Cohort A]: Patients with documented germinal mutation in BRCA1 or BRCA2 genes that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function).
  • 10. [Exploratory cohort B]: Patients with either germinal BRCA1/2 wild-type (gBRCAwt) or gBRCAms that are considered to be non- detrimental and homologous recombination deficiency (HRD) based on the HRDetect predictor test.
  • 11. [Exploratory cohort B]: Willingness and ability to provide additional six formalin-fixed paraffin-embedded (FFPE) tissue slides from the most recent tumor tissue since last progression (from either metastasis or primary tumor) to centrally perform the RAD51 assay.
  • 12. At least one and up to two prior lines of endocrine therapy (aromatase inhibitors [AIs] or fulvestrant) for treatment of locally recurrent and/or metastatic disease (except for patients progressing in the neoadjuvant or adjuvant setting).
  • 13. Confirmed disease progression while in the last AI-containing regimen (not necessarily in the treatment line immediately prior to study entry) with secondary endocrine resistance criteria.
  • 14. Patients may have progressed on no more than one chemotherapy regimens in the metastatic setting.
  • 15. The following will not be counted as a prior line of cytotoxic chemotherapy:

    • Prior hormonal therapy and non-hormonal targeted therapy.
    • Targeted and biologic therapies.
    • The patient can receive a stable dose of bisphosphonates or denosumab for bone metastases, before and during the study as long as this was started at least 5 days prior to study treatment.
  • 16. Prior carboplatin- or other platinum compound-based therapy is allowed if have been administered in one of the following settings:

    • Disease-free interval > 12 months from date of completion of neoadjuvant or adjuvant treatment.
    • As potentially curative treatment for a prior non-breast cancer with no evidence of disease for ≥ 5 years.
  • 17. Patients must have evaluable or measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1. Patient with bone-only metastases are eligible.
  • 18. Willingness and ability to provide the most recent tumor biopsy since last progression from either metastatic or primary tissues both at the time of the inclusion and at disease progression or study termination in order to perform exploratory studies.
  • 19. Patients must agree to provide blood samples at the time of study inclusion, every three cycles of treatment, and upon disease progression or study termination in order to perform exploratory studies.
  • 20. Adequate hematologic and organ function within 28 days before the first study treatment on Cycle 1 Day 1.
  • 21. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to study treatment and must agree to abstain from activities that could result in pregnancy from screening through 180 days after the last dose of study treatment.
  • 22. Female patients must agree not to breastfeed during the study and for 180 days after the last dose of study treatment.
  • 23. Male patients whose partners are women of childbearing potential must use a condom during niraparib therapy and for 90 days after receiving the last dose of niraparib.

Exclusion Criteria:

  • 1. HER2-positive disease based on local laboratory results (performed by IHC/in situ hybridization test) or unknown HER2 status.
  • 2. Patients that are candidates for a local treatment with a radical intention.
  • 3. Patients that have previously received any PARP inhibitor (PARPi), including niraparib, in metastatic setting.
  • 4. Patients must not be simultaneously enrolled in any interventional clinical trial and must not have received investigational therapy ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy.
  • 5. Patients who have had radiation therapy encompassing >20% of the bone marrow within 2 weeks prior to start of treatment, excepting for palliative radiation therapy to a small field >1 week prior to Day 1 of study.
  • 6. Patients with visceral crisis who require chemotherapy.
  • 7. Patients must not have a known hypersensitivity to niraparib components or excipients.
  • 8. Patients must not have received a transfusion (platelets or red blood cells) ≤ 4 weeks prior to initiating protocol therapy.
  • 9. Patients must not have received colony-stimulating factors (e.g., Granulocyte colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy.
  • 10. Patients have had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy in adjuvant setting or cyclin-dependent kinases (CDK)4/6 inhibitors that persisted > 4 weeks and was related to the most recent treatment.
  • 11. Patients must not have any known history of Myelodysplastic syndrome (MDS) or Acute myeloid leukemia (AML).

    12. Patients must not have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection.

  • 13. Patients must not have had diagnosis, detection, or treatment of another type of cancer ≤ 2 years prior to initiating protocol therapy.
  • 14. Patients with symptomatic uncontrolled brain metastases or leptomeningeal metastases.
  • 15. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
  • 16. Patients who are unable to swallow orally administered medication.
  • 17. Patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  • 18. Chronic daily treatment with corticosteroids with a dose of ≥ 10 mg/day methylprednisolone equivalent (excluding inhaled steroids), except for prophylaxis use.
  • 19. Female patients who are pregnant or breastfeeding, or adults of reproductive potential who are not using effective birth control methods.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04240106


Contacts
Layout table for location contacts
Contact: Almudena García 0034 610 688 562 almudena.garcia@medsir.org
Contact: Alicia Garcia 0034 611 261 467 alicia.garcia@medsir.org

Locations
Layout table for location information
Spain
Centro Oncologico de Galicia
A Coruña, Spain, 15009
Contact: Manuel Ramos, MD       manuel.ramos@cog.es   
Hospital Uniersitario Vall d'Hebron
Barcelona, Spain, 08035
Contact: Judith Balmaña, MD       jbalmana@vhio.net   
Hospital Clínic i provincial de Barcelona
Barcelona, Spain, 08036
Contact: Aleix Prat, MD       ALPRAT@clinic.cat   
Hospital Universitario Reina Sofía
Córdoba, Spain, 28091
Contact: Juan De la Haba, MD       juahaba@gmail.com   
Hospital Clinico San Carlos
Madrid, Spain, 28041
Contact: Jose Angel García Saénz, MD       jagsaenz@yahoo.com   
Hospital Universitario 12 de octubre
Madrid, Spain, 28041
Contact: Laura Lema, MD       laura.lema@gmail.com   
Hospital Universitario Virgen de la Victoria
Málaga, Spain, 29010
Contact: Emilio Alba, MD       ealbac@uma.es   
Hospital Clínico Universitario de Santiago de Compostela
Santiago De Compostela, Spain, 15706
Contact: Patricia Palacios, MD       onco.chop@yahoo.es   
Instituto Valenciano de Oncología
Valencia, Spain, 46009
Contact: Salvador Blanch Tormo, MD       salvabtormo@gmail.com   
Complejo Asistencial de Ávila
Ávila, Spain, 05071
Contact: Jose Enrique Alés, MD       jeales@saludcastillayleon.es   
Sponsors and Collaborators
MedSIR
GlaxoSmithKline
Investigators
Layout table for investigator information
Principal Investigator: Antonio LLombart MedSIR
Layout table for additonal information
Responsible Party: MedSIR
ClinicalTrials.gov Identifier: NCT04240106    
Other Study ID Numbers: MedOPP190
First Posted: January 27, 2020    Key Record Dates
Last Update Posted: January 28, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MedSIR:
BRCA mutations
homologous recombination deficiency
Luminal like
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Niraparib
Aromatase Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Steroid Synthesis Inhibitors
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs